Latest Insights - page 72 | BiopharmaTrend

Navigating the Crossroads of AI and Oncology: A Deep Dive with Lantern Pharma's CEO, Panna Sharma

Busting the PoseBusters v3: AI Docking Software ArtiDock Beats Industry’s State of the Art in Speed and Accuracy

In an Industry First, Veeva Migrates Study Portfolio of Top 20 Biopharmas to Vault EDC

Veeva Systems, a prominent player in cloud-based software for the global life sciences industry, has successfully migrated a significant portfolio of ongoing clinical studies for a top 20 biopharmaceutical company. …

Continue ›››

Innovative Approach to Combat Arthritis: Mesenbio's Stem Cell Therapy

Mesenbio, a pioneering biotechnology firm emerging from the University of York, has recently secured a significant £1.4 million investment. This funding round, co-led by DSW Ventures and NG Bio, along …

Continue ›››

Conducting a Cellular Symphony With Life Saving Combination Therapies

I always think of the Jeff Goldblum quote in Jurassic Park where he says "life finds a way" when I think of cancer. However, I simply substitute the word life …

Continue ›››

Playing Chess Against Cancer: A Pharmaceutical, Biotechnological, and Clinical Guide to Modern Day Oncologic Treatment Cartography

We are witnessing a revolution in cancer therapeutics that is truly bewildering. The number of novel drugs with unique mechanisms of action currently in clinical trial and development is staggering, …

Continue ›››

Quarterbacking a Patient's Fight Against Cancer

In the incredibly competitive world of drug development, comprehensive precision, and healthtech, every strategic control point is essential. Over the next several months, during this editorial series, we will admittedly …

Continue ›››

Drowning in Data: A Data Science Primer for a Translational Scientist

In 1945 the volume of human knowledge doubled every 25 years. Now, that number is 12 hours [1]. With our collective computational power rapidly increasing, vast amounts of data and …

Continue ›››

Predicting a Patient’s Future with a Crystal Ball Comprised of Cell-free DNA

Chapter 1 of a 3-chapter Hitchhiker’s guide to cell-free DNA for travelers of all backgrounds and expertise. Even though I’ve been a hematologist/oncologist for over a decade, I’m horrendous at …

Continue ›››

Hunting Cancer Before It Can Hunt You: A Bird's Eye View of Cell-Free DNA Market Trends

Chapter 2 of a Hitchhiker's Guide to Cell-Free DNA. By the end of 2022, there will be an estimated 609,360 deaths cause by cancer in the US alone [1]. In …

Continue ›››

Wielding New Cancer Weapons Forged in Cell-Free DNA: A Wake Up Call For The Entire Biotech Industry

Advances in computational biology, precision medicine, artificial intelligence/machine learning, etc., are launching us into a world where strategic control points in drug discovery, pharmaceuticals, clinical trials, etc., will never be …

Continue ›››

A Proof-of-Concept Study Towards Novel ALS Therapy

Verge Genomics, a clinical-stage biotechnology company, has just initiated a Phase 1b proof-of-concept study for VRG50635, a drug developed for the treatment of amyotrophic lateral sclerosis (ALS), also known as …

Continue ›››